[The influence of additive clonal chromosome abnormalities in Ph negative cells on the efficacy of chronic myeloid leukemia]

Zhonghua Nei Ke Za Zhi. 2019 Nov 1;58(11):803-807. doi: 10.3760/cma.j.issn.0578-1426.2019.11.003.
[Article in Chinese]

Abstract

Objective: To investigate the influence of additional clonal chromosome abnormalities in Ph negative cells (CCA/Ph(-)) on the efficacy of chronic myeloid leukemia (CML) after tyrosine kinase inhibitors (TKI) treatment. Methods: The clinical data of 28 CML patients with CCA/Ph(-) treated in Henan Cancer Hospital from July 2014 to December 2017 were analyzed retrospectively. The univariate analysis was carried out by Kaplan-Meier method. Multivariate analysis was done by Cox proportional risk model. Results: A total of 28 CCA/Ph(-)patients were recruited including 17 males and 11 females with median age of 42.5 years old. The most common CCA/Ph(-)were trisomy 8 (60.7%), monosomy 7 (14.3%). 64.3% CCA/Ph(-)were transient and 35.7% recurrent (more than 2 times). Cytopenia in two or three lineages of peripheral blood was seen in 42.9% patients. As to the efficacy, 89.3% patients achieved major cytogenetic response (MCyR), 25% with major molecular response (MMR). The median follow-up time was 26.5 months. Treatment failure (TF) of TKI occurred in 32.1% patients with median duration of response 8 (1-41) months. Univariate analysis showed that TF rate was significantly correlated with the frequency of CCA/Ph(-)and cytopenia (all P<0.05). The MMR rate was also significantly correlated with cytopenia (P<0.05). Cytopenia of two lineages or pancytopenia was an independent risk factor related to MMR rate (RR=3.868, 95%CI 1.216-12.298, P=0.022) . Conclusions: Cytopenia in CCA/Ph(-)appears to be an independent risk factor of MMR in CML patients with TKI treatment. The recurrent CCA/Ph(-)may link to higher treatment failure rate. Drug withdrawal or alternative strategy should be considered according to response and the ABL kinase mutations.

目的: 探讨酪氨酸激酶抑制剂(TKI)治疗期间费城染色体阴性细胞出现克隆性染色体异常(CCA/Ph(-))对慢性髓性白血病(CML)治疗疗效的影响。 方法: 回顾性分析河南省肿瘤医院2014年7月至2017年12月检出CCA/Ph(-)的28例CML患者的临床资料。单因素分析采用Kaplan-Meier法,多因素分析采用Cox比例风险模型法。 结果: 纳入28例CML患者,男17例,女11例,首次检出CCA/Ph(-)时患者的中位年龄为42.5岁。CCA/Ph(-)以+8为主异常最常见,占60.7%,7号染色体为主异常占14.3%。64.3%的CCA/Ph(-)呈一过性出现,35.7%为反复出现(出现次数≥2次)。42.9%患者血象呈二系或三系减低。89.3%患者获主要细胞遗传学反应(MCyR),25.0%患者获主要分子学反应(MMR)。中位随访26.5个月。至随访结束,32.1%患者TKI治疗失败,中位无失败治疗时间为8(1~41)月。单因素分析显示:CCA/Ph(-)出现频率、CCA/Ph(-)出现时血象是否正常等因素与治疗失败有关联(P值均<0.05);CCA/Ph(-)出现时血象是否正常与MMR率有关联(P<0.05)。多因素分析显示:CCA/Ph(-)出现时血象两系或三系减低是影响MMR率的独立危险因素(RR=3.868,95%CI 1.216~12.298,P=0.022),但对治疗失败率的影响不显著。 结论: TKI治疗期间CCA/Ph(-)出现时伴血象两系或三系减低是影响CML患者MMR率的独立危险因素。CCA/Ph(-)反复出现者的治疗失败率较CCA/Ph(-)一过性出现者显著升高。TKI治疗期间出现CCA/Ph(-)时血象减低者是否需要停药、减量或更换其他TKI治疗,应结合CML治疗反应和ABL激酶区突变综合评估。.

Keywords: Chromosomal abnormalities; Leukemia, myeloid, chronic; Philadelphia chromosome-negative cells; Treatment outcome; Tyrosine kinase inhibitors.

MeSH terms

  • Adult
  • Chromosome Aberrations*
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Male
  • Middle Aged
  • Mutation
  • Prognosis
  • Protein Kinase Inhibitors / therapeutic use*
  • Retrospective Studies
  • Treatment Failure

Substances

  • Protein Kinase Inhibitors